Basilea Pharmaceutica Ltd.

Basilea Pharmaceutica Ltd. is a commercial-stage, globally recognized biopharmaceutical company focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives. Forge and Basilea entered into a multi-target agreement to apply Forge’s proprietary BLACKSMITH metalloenzyme chemistry platform to develop potent and selective inhibitors against two historically difficult-to-drug, unexploited antibiotic targets. Forge is eligible to receive payments of up to $167M per target and tiered royalties upon commercialization of each antibiotic stemming from the collaboration.


Evotec is a leading global drug discovery partnership organization with expertise in multiple therapeutics areas including infectious disease. Forge & Evotec formed a strategic relationship in 2016 to advance the LpxC program and expanded in 2017 to further develop the BLACKSMITH platform. In addition, Evotec is an investor in Forge’s Series A financing.


CARB-X is the world’s largest public-private partnership dedicated to supporting the discovery of antibiotics targeting Gram-negative bacteria. CARB-X has over $450M in funding to support a portfolio of new innovative drug discovery programs. Forge was the largest recipient of the inagural CARB-X awards.


Forge has been collaborating with NIAID since 2015 to develop key datasets to help advance its anti-infective programs.


Forge has initiated a collaboration with USAMRIID to investigate medical counter measures for biodefense.